CDH1 (also known as
E-cadherin), an epithelial-specific cell-
cell adhesion molecule, plays multiple roles in maintaining adherens junctions, regulating migration and invasion, and mediating intracellular signaling. Downregulation of
E-cadherin is a hallmark of epithelial-to-mesenchymal transition (EMT) and correlates with poor prognosis in multiple
carcinomas. Conversely, upregulation of
E-cadherin is prognostic for improved survival in
sarcomas. Yet, despite the prognostic benefit of
E-cadherin expression in
sarcoma, the mechanistic significance of
E-cadherin in
sarcomas remains poorly understood. Here, by combining mathematical models with wet-bench experiments, we identify the core regulatory networks mediated by
E-cadherin in
sarcomas, and decipher their functional consequences. Unlike
carcinomas,
E-cadherin overexpression in
sarcomas does not induce a mesenchymal-to-epithelial transition (MET). However,
E-cadherin acts to reduce both anchorage-independent growth and spheroid formation of
sarcoma cells. Ectopic
E-cadherin expression acts to downregulate phosphorylated CREB1 (p-CREB) and the
transcription factor, TBX2, to inhibit anchorage-independent growth. RNAi-mediated knockdown of TBX2 phenocopies the effect of
E-cadherin on CREB levels and restores sensitivity to anchorage-independent growth in
sarcoma cells. Beyond its signaling role,
E-cadherin expression in
sarcoma cells can also strengthen cell-cell adhesion and restricts spheroid growth through mechanical action. Together, our results demonstrate that
E-cadherin inhibits
sarcoma aggressiveness by preventing anchorage-independent growth. IMPLICATIONS: We highlight how
E-cadherin can restrict aggressive behavior in
sarcomas through both biochemical signaling and biomechanical effects.